Catalyst Pharmaceuticals Inc’s recently made public that its Chief Strategy Officer Sundaram Preethi unloaded Company’s shares for reported $61377.0 on Jun 10 ’25. In the deal valued at $26.41 per share,2,324 shares were sold. As a result of this transaction, Sundaram Preethi now holds 42,681 shares worth roughly $1.01 million.
Then, Sundaram Preethi sold 1,600 shares, generating $42,272 in total proceeds. Upon selling the shares at $26.42, the Chief Strategy Officer now owns 41,081 shares.
Before that, Sundaram Preethi bought 1,600 shares. Catalyst Pharmaceuticals Inc shares valued at $42,268 were divested by the Officer at a price of $26.42 per share.
Robert W. Baird initiated its Catalyst Pharmaceuticals Inc [CPRX] rating to an Outperform in a research note published on February 04, 2025; the price target was $28. A number of analysts have revised their coverage, including Stephens’s analysts, who began to cover the stock in mid November with a ‘”an Overweight”‘ rating. Citigroup began covering CPRX with “Buy” recommendation on March 14, 2024. BofA Securities started covering the stock on March 07, 2024. It rated CPRX as “a Buy”.
Price Performance Review of CPRX
On Monday, Catalyst Pharmaceuticals Inc [NASDAQ:CPRX] saw its stock jump 0.59% to $23.67. Over the last five days, the stock has lost -8.40%. Catalyst Pharmaceuticals Inc shares have risen nearly 13.42% since the year began. Nevertheless, the stocks have risen 53.20% over the past one year. While a 52-week high of $26.58 was reached on 06/09/25, a 52-week low of $14.75 was recorded on 01/08/25.
Levels Of Support And Resistance For CPRX Stock
The 24-hour chart illustrates a support level at 23.40, which if violated will result in even more drops to 23.14. On the upside, there is a resistance level at 23.92. A further resistance level may holdings at 24.18.
The most recent change occurred on December 21, 2023 when Oppenheimer began covering the stock and recommended ‘”an Outperform”‘ rating along with a $30 price target.
